My Eyes

What is My Eyes?

Receiving a diagnosis of macular disease can be challenging. People tell us they feel many emotions ranging from disbelief, apprehension and even depression.

It’s normal to feel this way, and we’re here to help.

Introducing My Eyes, your guide to living with macular disease.

For more than 20 years, Macular Disease Foundation Australia (MDFA) has been working for the approximately 1.9 million Australians living with macular disease, their families, and carers.

My Eyes is a service developed by MDFA in collaboration with patients, carers, and eye care professionals, to ensure those living with the disease get the best care between visits to their optometrist or ophthalmologist.

My Eyes is free of charge, independent and endorsed by Australia’s leading eye health professionals. The service focuses on three areas:

• Health information. We’ll provide you with evidence-based information about macular disease, non-clinical support services to help you confidently manage your condition,
• Practical advice. Tips and guidance on things like nutrition for healthy eyes, immediate care after your appointment, daily living with reduced or low vision, and even travel tips.
• Emotional support. For some, a diagnosis of macular disease – or living with an eye condition – can be a difficult time. Our My Eyes team can help you manage some of the worries and concerns you may have about your diagnosis and treatment. We can also connect you to peer support.

My Eyes will provide support over an extended period, enabling you to better understand and manage life with macular disease. This support is available through phone, email, via our electronic newsletter and through printed resources, depending on your preference.

Joining My Eyes is easy. Once you complete the contact form, one of our friendly team members will be in touch within two business days, to get you started.

My Eyes is proudly supported through the generosity of corporate sponsors and community donations. We wish to extend our thanks to the macular disease community, as well as Apellis, Novartis, and Roche in Australia.